Quick Answer
Zura Bio Ltd reported Cash and Equivalents of $109.41 million for fiscal year 2025.
Zura Bio Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $109.41M | -38.0% |
| 2024 | $176.50M | +76.8% |
| 2023 | $99.81M | +723918.9% |
| 2022 | $13.8K | -98.1% |
| 2021 | $729.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $139.02M | -26.1% | -10.0% |
| June 30, 2025 | $154.49M | — | -9.4% |
| March 31, 2025 | $170.57M | — | -3.4% |
| December 31, 2024 | $176.50M | +76.8% | -6.2% |
| September 30, 2024 | $188.22M | — | +88.6% |
| December 31, 2023 | $99.81M | — | +133952.4% |
| September 30, 2022 | $74.5K | -92.5% | -66.3% |
| June 30, 2022 | $220.7K | +783.8% | -57.1% |
- Zura Bio Ltd showed a decrease of -38.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Zura Bio Ltd’s cash and equivalents has grown by 14903.2% (from $729.2 thousand to $109.41 million).
- The most recent figure is from Zura Bio Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: